CEFAGEN ORAL SUSPENSION CEFUROXIME 125MG/5ML 50ML

Product Description

Cefuroxime axetil is used by V.O. for the treatment of mild to moderate respiratory tract infections (acute maxillary sinusitis, acute exacerbations of chronic bronchitis, secondary infections of acute bronchitis, community-acquired pneumonia) caused by susceptible bacteria; Acute bacterial otitis media, pharyngitis and tonsillitis caused by Streptococcus pyogenes (group A ß-hemolytic); Uncomplicated mild to moderate skin infections caused by Staphylococcus aureus (including ß-lactamase producing strains) or S. pyogenes, and uncomplicated urinary tract infections caused by Escherichia coli or Klebsiella pneumoniae. Cefuroxime axetil is also used by V.O. for the treatment of uncomplicated gonorrhea and for the treatment of Lyme disease. The efficacy of (cefuroxime axetil) is reported to have been established only for the treatment of pharyngitis and tonsillitis, acute otitis media, and impetigo caused by susceptible bacteria. And for the treatment of Lyme disease. Because cefuroxime, like other second-generation cephalosporins in general, is less active against gram-positive cocci than first-generation cephalosporins, most clinicians state that cefuroxime should probably not be used in the treatment of infections caused by gram-positive bacteria when a first-generation penicillin or cephalosporin could be used. Additionally, because cefuroxime is generally less active in vitro against enterobacteria than third-generation cephalosporins, some clinicians claim that a third-generation drug such as cefotaxime or ceftriaxone is generally preferred if a parenteral cephalosporin is indicated for treatment. of infections caused by these gram-negative bacteria. Before initiation of therapy with cefuroxime, samples should be obtained for identification of the causative organism and in vitro susceptibility testing. If cefuroxime is started pending the results of susceptibility testing, it should be stopped if the causative organism is found resistant. In the treatment of sepsis, when the causative organism is unknown, concomitant therapy with an aminoglycoside may be indicated while awaiting results of in vitro susceptibility tests.